Enorama Pharma AB (ERMA) Stock Statistics & Valuation Metrics

Enorama Pharma AB has a market cap or net worth of kr26.85M. The enterprise value is kr23.81M.

Enorama Pharma AB has 74,588,684 shares outstanding. The number of shares has decreased by -2.65% in one year.

Enorama Pharma AB’s return on equity (ROE) is 3.20 and return on invested capital (ROIC) is 264.89%.

The current PE Ratio of Enorama Pharma AB is ―. Enorama Pharma AB’s PEG ratio is -0.06.

In the last 12 months, Enorama Pharma AB had revenue of 2.74M and earned -75.14M in profits. Earnings per share was -1.08.

In the last 12 months, operating cash flow was -59.26M and capital expenditures 14.79M, giving a free cash flow of -44.47M billion.

Enorama Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Enorama Pharma AB upcoming earnings date is May 20, 2026, TBA (Confirmed).

Enorama Pharma AB as a current ratio of 0.25, with Debt / Equity ratio of 0.00%

In the past 12 months, Enorama Pharma AB has paid 0.00 in taxes.

Enorama Pharma AB EV to EBITDA ratio is -2.10, with an EV/FCF ratio of 0.00.

Enorama Pharma AB has kr3.04M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr3.04M billion.

Gross margin is -1490.03%, with operating margin of -2267.98%, and net profit margin of -2743.30%.

The average price target for Enorama Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―